Specialty Pharmacy

Study finds association between obesity and a greater burden of symptoms and distress among patients with breast or prostate cancer.

Puma’s supplemental New Drug Application is seeking approval for the use neratinib (Nerlynx) plus capecitabine as a third-line treatment in patients with human epidermal growth receptor 2-positive metastatic breast cancer.

New updates to immunization guidelines in multiple sclerosis outline recommendations on vaccination decisions for patients.

Dietary interventions that raise levels of high-density lipoprotein, or good cholesterol, may affect fatigue symptoms in multiple sclerosis.

An autopsy-based study examined long-term trends in HIV-related mortality among individuals living with the disease in New York City.

Results from a phase 2 study demonstrated complete tumor responses in patients with metastatic renal cell carcinoma treated with the combination lixadencel and sunitinib.

Novel combination may improve efficacy of immune checkpoint inhibitors in treating non-small cell lung cancer.

Nintedanib (Ofev, Boehringer Ingelheim) is now the first therapy approved for patients with interstitial lung disease associated with systemic sclerosis.

Two separate studies highlighted how high drug costs and requirements for prior authorization can hinder access to cancer treatment and affect outcomes.

Anifrolumab (AstraZeneca) demonstrated a statistically significant and clinically meaningful reduction in disease activity based on composite lupus assessment.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Voxelotor (Global Blood Therapeutics) is being developed for patients with sickle cell disease.

Oncologists suggest that substituting nab-paclitaxel instead of paclitaxel prior to surgery may lead to reduced risk of disease recurrence for certain women with breast cancer.

Top news of the day from across the health care landscape.

Health system specialty pharmacies are creating a more integrated care structure for complex patients on specialty drug regimens.

Building on the current understanding of spihingosine 1-phosphate levels in regulating T cell function, researchers found that the inhibition of the lipid can lead to more effective uses of immunotherapy in cancer therapy.

Top news of the day from across the health care landscape.

The study findings suggest that, while the link between chronic lymphocytic leukemia and melanoma had been known, the rate at which the link occurs is higher than expected.

Novel treatment approach combines a new immunotherapy with stem cell transplantation.

Top news of the day from across the health care landscape.

Specialty pharmacists play an important role in the selection of immunoglobulin G products and optimizing therapy for patients.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

ABP 798, a biosimilar candidate to rituximab (Rituxan), demonstrated clinical equivalence in a study of patients with non-Hodgkin lymphoma.

Top news of the day from across the health care landscape.

Rising drug prices for disease-modifying therapies resulted in substantial increases in spending for Medicare beneficiaries with multiple sclerosis.

Older women with breast cancer who have a concurrent mental health condition are more likely to use opioids and have worse survival outcomes.